

Attorney Docket No.: UIC0005US.NP
Inventors: Kumar et al.
Serial No.: Not yet assigned
Filing Date: Herewith
Page 4

This listing of the claims will replace all prior versions and listings of claims in the application:

Listing of the claims:

Claims 1-11 (canceled)

Claim 12 (new): An siRNA molecule that reduces expression of the TGF β type II receptor, wherein the siRNA molecule is 19-25 base pairs in length and targets at least a portion of the coding sequence of a nucleic acid molecule comprising the nucleic acid sequence of SEQ ID NO:159.

Claim 13 (new): A composition comprising the siRNA molecule of claim 12 and a pharmaceutically acceptable carrier.

Claim 14 (new): The composition of claim 13, further comprising a wound healing agent.

Claim 15 (new): A method for promoting wound healing in a mammal comprising administering a therapeutically effective amount of a composition comprising the siRNA molecule of claim 12 to a mammal in need of treatment.

Attorney Docket No.: UIC0005US.NP
Inventors: Kumar et al.
Serial No.: Not yet assigned
Filing Date: Herewith
Page 5

Claim 16 (new): A method for inhibiting fibrosis in a mammal comprising administering a therapeutically effective amount of a composition comprising the siRNA molecule of claim 12 to a mammal in need of treatment.

Claim 17 (new): A method for inhibiting angiogenesis in a mammal comprising administering a therapeutically effective amount of a composition comprising the siRNA molecule of claim 12 to a mammal in need of treatment.

Claim 18 (new): A method for preventing glaucoma in a mammal comprising administering to a mammal in need of treatment a therapeutically effective amount of a composition comprising the siRNA molecule of claim 12.

Claim 19 (new): A method of preventing restenosis in a mammal comprising administering to said mammal a therapeutically effective amount of a composition comprising the siRNA molecule of claim 12.

Claim 20 (new): A method of preventing or treating scarring in a mammal comprising administering to said mammal a therapeutically effective amount of a composition comprising the siRNA molecule of claim 12.